Apoptosis

KH16 is a potent and low nanomolar HDAC inhibitor.

TH9619 is a potent inhibitor of dedrogenase and cyclodrolase activities in both MTHFD1 and MTHFD2 with a IC50 value of 47 nM, and selectively kills cancer cells.

UCM-1336 is a potent ICMT inhibitor, with an IC50 of 2 μM.

HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor.

FB49 is a highly selective inhibitor of Bcl-2-associated athanogene 3 (BAG3), with the Ki of 45 μM.

ZZM-1220 is a histone lysine metltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively.

FPR1 antagonist 1 (compound 24a) is a formyl peptide receptor 1 (FPR1) antagonist with an IC50 of 25 nM.

NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3.

Cu(II)-Elesclomol is a 1:1 chelate formed by Elesclomol and Cu (II) ions, which can induce copper death and has anti-cancer activity.

NBI-961 is a potent NEK2 inhibitor that inhibits proteasomal degradation.

RMC-4998 is an orally active inhibitor targeting the active or GTP-bound state of the KRASG12C mutant.

droxy-PP-Me is a potent and specific CBR1 inhibitor with an IC50 of 759 nM.

STM3006 is a highly potent, selective and orally active METTL3 inhibitor (IC50: 5 nM).

DCZ5418 is an inhibitor of TRIP13.

JAB-2485 is a potent and selective Aurora kinase A (AURKA) inhibitor, with an IC50 of 0.33 nM.

Trilexium (TRX-E-009-1) is a third-generation of benzopyran structurally related to TRX-E-002-1.

PKM2-IN-6 (compound 7d) is a potent and orally active PKM2 inhibitor with an IC50 value of 23 nM.

PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively.

YCH2823 is an inhibitor of USP7 (IC50 = 49.6 nM; Kd = 0.117 μM).

T-1-PMPA is a potent EGFR inhibitor with apoptotic properties.

Glutor is a selective GLUT 1/2/3 inhibitor that can suppress glucose uptake.

IOX5 is a selective prolyl droxylases (PHD) inhibitor.

GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively.

WD6305 TFA is a potent METTL3-targeted PROTAC degrader.